Therapeutic Potential of Itolizumab: Mechanisms, Efficacy and Clinical Applications

Itolizumab, a humanized recombinant monoclonal antibody targeting the SRCR-D1 region of CD6, exhibits therapeutic potential in various medical conditions. This review encompasses its molecular characteristics, pharmacokinetics, pharmacodynamics, mechanism of action and the production flow chart. Commercially available as Alzumab™, Itolizumab's linear, dose- dependent relationship in Cmax, increased accumulation with higher dosing frequency, and variable half-life reveal key pharmacokinetic features. Itolizumab's safety margin is established through toxicity studies, and its suggested dosage is outlined. Itolizumab emerges as a versatile therapeutic option, demonstrating efficacy in autoimmune disorders, infectious diseases like COVID-19, and chronic conditions like psoriasis, rheumatoid arthritis and diabetes, Multiple Sclerosis (MS) and Inflammatory Bowel Disease (IBD). Further structural exploration and clinical trials are warranted to explore its therapeutic potential and elucidate its long-term safety profile.